Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TTX-MC138-NODAGA-Cu64 · 1 trial · 1 indication
Measure the percent injected dose per cubic centimeter (%ID/cc) tissue of TTX-MC138-NODAGA-Cu64 in radiographically confirmed metastatic lesions in subjects with advanced solid tumors using PET-MRI.
| Name | Type | Description |
|---|---|---|
| TTX-MC138-NODAGA-Cu64 | DRUG | TTX-MC138-NODAGA-Cu64 solution was developed as a PET radiopharmaceutical to permit assessment of delivery of TMX-MC138 to metastatic lesions in subjects with solid tumors. Subjects will be administered a microdose of TTX-MC138-NODAGA-Cu64 injection administered intravenously followed by whole body PET imaging. |
Inclusion Criteria: 1. Willing and able to provide written informed consent form for the study prior to the performance of any study-specific procedures. 2. Greater than or equal to 18 years of age at the time of screening. 3. Histologically or cytologically confirmed diagnosis of metastatic solid ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
TTX-MC138-NODAGA-Cu64 is an investigational small molecule being developed for advanced solid tumors. It is currently in Phase 1 clinical development as a microdose study in subjects with advanced solid tumors. The drug has received orphan drug designation from the FDA.
TTX-MC138-NODAGA-Cu64 is being developed by TransCode Therapeutics, Inc. (NASDAQ: RNAZ). The company is conducting clinical trials for this investigational drug in the United States.
TTX-MC138-NODAGA-Cu64 is in Phase 1 clinical development. A microdose study in subjects with advanced solid tumors has been completed. The drug is investigational and not yet approved by the FDA.
TTX-MC138-NODAGA-Cu64 has one completed clinical trial, NCT05908773, titled 'A Microdose Study of TTX-MC138-NODAGA-Cu64 in Subjects With Advanced Solid Tumors.' This early Phase 1 study enrolled one participant in the United States.
TTX-MC138-NODAGA-Cu64 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for advanced solid tumors. The FDA has granted it orphan drug designation, but it remains in clinical testing.